FOXM1 and cancer: Consonant with these observations, siRNA knockdown or pharmacological inhibition of FOXM1 abrogated all of the effects associated with cancer-driving FOXM1 activity, validating FOXM1 as a promising target for suppression of different breast cancers [28, 37, 38, 59, 64, 65].